ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

BPMC Blueprint Medicines Corporation

85.18
-2.07 (-2.37%)
Apr 15 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 506,386
Bid Price 81.10
Ask Price 91.63
News -
Day High 87.835

Low
43.89

52 Week Range

High
101.00

Day Low 84.33
Company Name Stock Ticker Symbol Market Type
Blueprint Medicines Corporation BPMC NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-2.07 -2.37% 85.18 20:00:00
Open Price Low Price High Price Close Price Prev Close
87.18 84.33 87.835 85.18 87.25
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
10,651 506,386 $ 85.78 $ 43,438,324 - 43.89 - 101.00
Last Trade Time Type Quantity Stock Price Currency
19:23:19 10 $ 87.06 USD

Blueprint Medicines Corporation Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
5.22B 61.23M - 249.38M -506.98M -8.28 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Blueprint Medicines News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No BPMC Message Board. Create One! See More Posts on BPMC Message Board See More Message Board Posts

Historical BPMC Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week92.3393.9384.3390.81506,128-7.15-7.74%
1 Month90.8697.0084.3390.35697,300-5.68-6.25%
3 Months81.88101.0072.2487.72787,3203.304.03%
6 Months48.86101.0043.8978.47837,41536.3274.33%
1 Year47.20101.0043.8968.63724,71337.9880.47%
3 Years96.71117.8637.8267.57646,888-11.53-11.92%
5 Years80.25125.6137.8271.89598,4294.936.14%

Blueprint Medicines Description

Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates BLU-285, which targets KIT Exon 17 mutants and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants that are drivers of cancer and proliferative disorders. Its other drug candidate is BLU 554 FOR Advanced Hepatocellular Carcinoma, and BLU-667 for Ret Mutations, Fusions, and Predicted Resistant Mutants.

Your Recent History

Delayed Upgrade Clock